tetano
Editor, Senior Moderator
Colloids Surf B Biointerfaces. 2018 Nov 15;174:536-543. doi: 10.1016/j.colsurfb.2018.11.031. [Epub ahead of print]
[h=1]Novel imiquimod nanovesicles for topical vaccination.[/h] Caimi AT[SUP]1[/SUP], Altube MJ[SUP]1[/SUP], de Farias MA[SUP]2[/SUP], Portugal RV[SUP]2[/SUP], Perez AP[SUP]1[/SUP], Romero EL[SUP]1[/SUP], Morilla MJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Development of needle and pain free noninvasive immunization procedures is a top priority for public health agencies. In this work the topical adjuvant activity of the immunomodulator imiquimod (IMQ) carried by ultradeformable archaeosomes (UDA[SUB]2[/SUB]) (nanovesicles containing sn-2,3 ether linked phytanyl saturated archaeolipids) was surveyed and compared with that of ultradeformable liposomes lacking archaeolipids (UDL[SUB]2[/SUB]) and free IMQ, using the model antigen ovalbumin and a seasonal influenza vaccine in Balb/c mice. UDA[SUB]2[/SUB] (250 ? 94 nm, -26 ? 4 mV Z potential) induced higher IMQ accumulation in human skin and higher production of TNF-α and IL-6 by macrophages and keratinocytes than free IMQ and UDL[SUB]2[/SUB]. Mixed with ovalbumin, UDA[SUB]2[/SUB] was more efficient at generating cellular response, as measured by an increase in serum IgG2a and INF-γ production by splenocytes, compared with free IMQ and UDL[SUB]2[/SUB]. Moreover, mixed with a seasonal influenza vaccine UDA[SUB]2[/SUB] produced same IgG titers and IgG2a/IgG1 isotypes ratio (≈1) than the subcutaneously administered influenza vaccine. Topical UDA[SUB]2[/SUB] however, induced highest stimulation index and INF-γ levels by splenocytes. UDA[SUB]2[/SUB] might be a promising adjuvant for topical immunization, since it produced cell-biased systemic response with ≈ 13-fold lower IMQ dose than the delivered as the commercial IMQ cream, Aldara.
[h=4]KEYWORDS:[/h] Archaeolipids; Cellular response; Immunomodulator; Influenza vaccine
PMID: 30500742 DOI: 10.1016/j.colsurfb.2018.11.031
[h=1]Novel imiquimod nanovesicles for topical vaccination.[/h] Caimi AT[SUP]1[/SUP], Altube MJ[SUP]1[/SUP], de Farias MA[SUP]2[/SUP], Portugal RV[SUP]2[/SUP], Perez AP[SUP]1[/SUP], Romero EL[SUP]1[/SUP], Morilla MJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Development of needle and pain free noninvasive immunization procedures is a top priority for public health agencies. In this work the topical adjuvant activity of the immunomodulator imiquimod (IMQ) carried by ultradeformable archaeosomes (UDA[SUB]2[/SUB]) (nanovesicles containing sn-2,3 ether linked phytanyl saturated archaeolipids) was surveyed and compared with that of ultradeformable liposomes lacking archaeolipids (UDL[SUB]2[/SUB]) and free IMQ, using the model antigen ovalbumin and a seasonal influenza vaccine in Balb/c mice. UDA[SUB]2[/SUB] (250 ? 94 nm, -26 ? 4 mV Z potential) induced higher IMQ accumulation in human skin and higher production of TNF-α and IL-6 by macrophages and keratinocytes than free IMQ and UDL[SUB]2[/SUB]. Mixed with ovalbumin, UDA[SUB]2[/SUB] was more efficient at generating cellular response, as measured by an increase in serum IgG2a and INF-γ production by splenocytes, compared with free IMQ and UDL[SUB]2[/SUB]. Moreover, mixed with a seasonal influenza vaccine UDA[SUB]2[/SUB] produced same IgG titers and IgG2a/IgG1 isotypes ratio (≈1) than the subcutaneously administered influenza vaccine. Topical UDA[SUB]2[/SUB] however, induced highest stimulation index and INF-γ levels by splenocytes. UDA[SUB]2[/SUB] might be a promising adjuvant for topical immunization, since it produced cell-biased systemic response with ≈ 13-fold lower IMQ dose than the delivered as the commercial IMQ cream, Aldara.
[h=4]KEYWORDS:[/h] Archaeolipids; Cellular response; Immunomodulator; Influenza vaccine
PMID: 30500742 DOI: 10.1016/j.colsurfb.2018.11.031